Literature DB >> 6677870

Aortic flow velocity curves in the diagnosis and the followup of symptomatic patent ductus arteriosus in preterm infants during therapeutic interventions.

H E Ulmer, G Knapp, D Wolf, L Wille, H W Seyberth.   

Abstract

In preterm infants, persistent ductus arteriosus (PDA) fails to close soon after birth and becomes symptomatic (sPDA) in about 40% of the infants, causing cardio-respiratory deterioration by a left-to-right shunt across the PDA. Aortic run-off of blood, predominantly occurring during ventricular diastole, causes an abnormal diastolic retrograde aortic blood flow. This aortic reverse flow can be assessed semi-quantitatively in a noninvasive way, using continuous-wave Doppler-ultrasonography. An increased ratio (R/F ratio) of the abnormal retrograde aortic blood flow (R) related to the normal forward flow (F) in the aorta indicates presence of sPDA in preterm infants. The R/F ratio was assessed in 30 premature infants, including 13 cases without sPDA, and 17 infants with sPDA--in 12 of them before and after surgical ligation of PDA, in five concomitantly to pharmacological closure of PDA by the application of indomethacin. The R/F ratio was low in all infants without sPDA and in infants following surgical ligation of PDA. On the other hand, a high R/F ratio was found in all patients with sPDA before specific treatment. During indomethacin-induced closure of PDA the R/F ratio decreased continuously, whereas it remained high in infants with sPDA not responding to indomethacin treatment.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6677870

Source DB:  PubMed          Journal:  Pediatr Pharmacol (New York)        ISSN: 0270-322X


  2 in total

1.  A preliminary study of the application of the transductal velocity ratio for assessing persistent ductus arteriosus.

Authors:  M W Davies; F R Betheras; M Swaminathan
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2000-05       Impact factor: 5.747

2.  Prolonged indomethacin treatment in preterm infants with symptomatic patent ductus arteriosus: efficacy, drug level monitoring, and patient selection.

Authors:  A Leonhardt; V Isken; P G Kühl; H W Seyberth
Journal:  Eur J Pediatr       Date:  1987-03       Impact factor: 3.183

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.